RAC3 and lung adenocarcinoma: To validate the notion that RAC3 promotes paclitaxel-resistant lung adenocarcinoma cell proliferation and survival through the activation of PI3K/AKT signaling, we treated A549 cells overexpressing RAC3 with 10 μM Ly294002, an inhibitor of PI3K.